Personalizing health care: feasibility and future implications.

Collapse authors list.
Godman, Brian ORCID: 0000-0001-6539-6972, Finlayson, Alexander E, Cheema, Parneet K, Zebedin-Brandl, Eva, Gutiérrez-Ibarluzea, Inaki ORCID: 0000-0002-4080-7963, Jones, Jan, Malmström, Rickard E, Asola, Elina, Baumgärtel, Christoph, Bennie, Marion et al (show 35 more authors) , Bishop, Iain, Bucsics, Anna, Campbell, Stephen ORCID: 0000-0002-2328-4136, Diogene, Eduardo, Ferrario, Alessandra, Fürst, Jurij, Garuoliene, Kristina ORCID: 0000-0001-7910-0108, Gomes, Miguel, Harris, Katharine, Haycox, Alan ORCID: 0000-0001-6659-4866, Herholz, Harald, Hviding, Krystyna, Jan, Saira, Kalaba, Marija, Kvalheim, Christina, Laius, Ott, Lööv, Sven-Ake, Malinowska, Kamila, Martin, Andrew, McCullagh, Laura ORCID: 0000-0001-8342-8739, Nilsson, Fredrik ORCID: 0000-0002-1905-4047, Paterson, Ken, Schwabe, Ulrich, Selke, Gisbert ORCID: 0000-0002-9614-9875, Sermet, Catherine, Simoens, Steven ORCID: 0000-0002-9512-2005, Tomek, Dominik ORCID: 0000-0003-0838-5550, Vlahovic-Palcevski, Vera, Voncina, Luka, Wladysiuk, Magdalena, van Woerkom, Menno, Wong-Rieger, Durhane, Zara, Corrine, Ali, Raghib and Gustafsson, Lars L ORCID: 0000-0002-0063-552X (2013) Personalizing health care: feasibility and future implications. BMC medicine, 11 (1). 179-.

Text PDF Godman, Finlayson et al.pdf - Published version Download (1MB)

Abstract

Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

Item Type:	Article
Additional Information:	## TULIP Type: Articles/Papers (Journal) ##
Uncontrolled Keywords:	Humans, Patient Care, Feasibility Studies, Pharmacogenetics, Forecasting, Delivery of Health Care, Precision Medicine
Depositing User:	Symplectic Admin
Date Deposited:	30 Jun 2017 07:52
Last Modified:	19 Jan 2023 07:01
DOI:	10.1186/1741-7015-11-179
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3008212